<DOC>
	<DOC>NCT00160173</DOC>
	<brief_summary>This study is intended to establish the lowest effective dose of EstroGelÂ® for the treatment of vasomotor symptoms associated with menopause.</brief_summary>
	<brief_title>Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Women 4565 years naturally or surgically postmenopausal experiencing hot flushes hypersensitivity to estrogen replacement therapy pregnancy or lactating abnormal PAP smear history/suspected cervical, uterine, adrenal, pituitary, breast or ovarian malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Post menopausal vasomotor symptoms</keyword>
</DOC>